Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Charcoal hemoperfusion for chronic renal failure

A W Siemsen, G Dunea, B H Mamdani

    Nephron
    |January 1, 1978
    PubMed
    Summary

    This study shows that charcoal hemoperfusion is a safe treatment for end-stage renal disease patients, effectively removing toxins like creatinine and uric acid. Further research is needed to confirm its long-term clinical benefits.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Vasculorama.

    The journal of vascular access·2013
    Same author

    Letter from Chicago: Out of the darkness.

    British medical journal (Clinical research ed.)·2010
    Same author

    Letter from Chicago: Reading aloud.

    British medical journal (Clinical research ed.)·2010
    Same author

    Letter from chicago: virgins of delft.

    British medical journal (Clinical research ed.)·2010
    Same author

    Letter from chicago: compulsion.

    British medical journal (Clinical research ed.)·2010
    Same author

    Letter from Chicago: Neither fish nor fowl.

    British medical journal (Clinical research ed.)·2010

    Area of Science:

    • Nephrology
    • Biomedical Engineering
    • Materials Science

    Background:

    • End-stage renal disease (ESRD) necessitates renal replacement therapy.
    • Hemoperfusion offers an alternative or supplementary method for toxin removal.

    Purpose of the Study:

    • To evaluate the safety and efficacy of uncoated-charcoal hemoperfusion in ESRD patients.
    • To assess the impact of hemoperfusion on blood parameters and toxin levels.

    Main Methods:

    • Sixteen ESRD patients underwent hemoperfusion using a fixed-bed, uncoated-charcoal device.
    • Treatments were administered either alone or in series with hemodialysis for varying durations and frequencies.
    • Device pretreatment with albumin or dextran was compared to heparinized saline.

    Main Results:

    • The hemoperfusion procedure was generally well-tolerated with transient hypotension observed.
    • Platelet counts decreased but without clinical bleeding; dextran exacerbated this effect.
    • Significant removal of creatinine and uric acid was achieved; hematological changes were transient.

    Conclusions:

    • Regular charcoal hemoperfusion is a safe adjunctive therapy for ESRD.
    • Long-term studies are warranted to establish the clinical efficacy of this treatment modality.

    Related Experiment Videos